Toward a Functional Cure for Hepatitis B
3
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as restoration of immune response to HBV. Direct-acting antivirals targeting virus entry, capsid assembly, viral protein production and secretion are in clinical trials. In parallel, immune modulatory therapies to stimulate HBV-specific immune response and to remove immune blockade are being tested. Clinical trials of direct-acting antivirals alone or immune modulatory therapies alone have not been successful in achieving HBV cure. Recent combinations of direct-acting antivirals and immune modulatory therapies have shown promising results particularly with combinations that included pegIFN-α. These results need to be confirmed in larger studies with longer follow-up, and further work is needed to develop simpler regimens with fewer drugs that can be administered orally and safely. While there is a strong desire to develop finite therapies that can achieve HBV cure, safety is paramount and new therapies must provide incremental value compared to standard of care, which is predominantly long-term NA therapy.
Abstract
Current treatment of chronic hepatitis B virus (HBV) infection, pegylated interferon-α (pegIFN-α) and nucleos(t)ide analogue (NA), can suppress HBV replication, reverse liver inflammation and fibrosis, and decrease risks of cirrhosis and hepatocellular carcinoma, but hepatitis B surface antigen (HBsAg) loss is rare. Functional HBV cure is defined as undetectable HBsAg and unquantifiable serum HBV DNA for at least 24 weeks after a finite course of therapy. This requires suppression of HBV replication and viral protein production as well as restoration of immune response to HBV. Direct-acting antivirals targeting virus entry, capsid assembly, viral protein production and secretion are in clinical trials. In parallel, immune modulatory therapies to stimulate HBV-specific immune response and to remove immune blockade are being tested. Clinical trials of direct-acting antivirals alone or immune modulatory therapies alone have not been successful in achieving HBV cure. Recent combinations of direct-acting antivirals and immune modulatory therapies have shown promising results particularly with combinations that included pegIFN-α. These results need to be confirmed in larger studies with longer follow-up, and further work is needed to develop simpler regimens with fewer drugs that can be administered orally and safely. While there is a strong desire to develop finite therapies that can achieve HBV cure, safety is paramount and new therapies must provide incremental value compared to standard of care, which is predominantly long-term NA therapy.
참고문헌 (46)
- Rehermann B, "Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection", J Clin Invest, 97, pp.1655~1665 (1996)
- Boni C, "Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues", Gastroenterology, 143, pp.963~973 (2012)
- Ko C, "Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels", J Hepatol, 69, pp.1231~1241 (2018)
- Lucifora J, "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA", Science, 343, pp.1221~1228 (2014)
- Boyd A, "Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients", J Hepatol, 65, pp.683~691 (2016)
- Wooddell CI, "RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg", Sci Transl Med, 9, pp.eaan0241~ (2017)
- Agarwal K, "A case of HBV-induced liver failure in the REEF-2 phase II trial : implications for finite treatment strategies in HBV ‘cure’", J Hepatol, 77, pp.245~248 (2022)
- Lok AS, "Hepatitis B cure : from discovery to regulatory approval", Hepatology, 66, pp.1296~1313 (2017)
- Cornberg M, "Guidance for design and endpoints of clinical trials in chronic hepatitis B: report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference", J Hepatol, 72, pp.539~557 (2020)
- Ghany MG, "Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D:report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference", Hepatology, 78, pp.1654~1673 (2023)
- Sonneveld MJ, "Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels", J Hepatol, 76, pp.1042~1050 (2022)
- Pavlovic V, "Peginterferon alfa-2a(40 kD)stopping rules in chronic hepatitis B : a systematic review and meta-analysis of individual participant data", Antivir Ther, 24, pp.133~140 (2019)
- Yuen MF, "Efficacy and safety of bepirovirsen in chronic hepatitis B infection", N Engl J Med, 387, pp.1957~1968 (2022)
- Lok AS, "Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B", Hepatol Commun, 4, pp.8~20 (2019)
- Yip TC, "How do we determine whether a functional cure for HBV infection has been achieved?", Clin Gastroenterol Hepatol, 18, pp.548~550 (2020)
- Buster EH, "Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b", Gastroenterology, 135, pp.459~467 (2008)
- Marcellin P, "Hepatitis B surface antigen levels : association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients", Hepatol Int, 7, pp.88~97 (2013)
- Jeng WJ, "Should treatment indications for chronic hepatitis B be expanded?", Clin Gastroenterol Hepatol, 19, pp.2006~2014 (2021)
- Flink HJ, "Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B : HBsAg loss is associated with HBV genotype", Am J Gastroenterol, 101, pp.297~303 (2006)
- Hadziyannis SJ, "Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir", Gastroenterology, 143, pp.629~636 (2012)
- Jeng WJ, "Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B", Hepatology, 68, pp.425~434 (2018)
- Berg T, "Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients : FINITE study", J Hepatol, 67, pp.918~924 (2017)
- van Bömmel F, "A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B", J Hepatol, 78, pp.926~936 (2023)
- Liem KS, "Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B : results from a randomised controlled trial(Toronto STOP study)", Gut, 68, pp.2206~2213 (2019)
- Feld JJ, "Withdrawal of long-term nucleotide analog therapy in chronic hepatitis B : outcomes from the withdrawal phase of the HBRN immune active treatment trial", Am J Gastroenterol, 118, pp.1226~1236 (2023)
- Hirode G, "Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B : an international, multicenter, multiethnic cohort(RETRACT-B Study)", Gastroenterology, 162, pp.757~771 (2022)
- Liu J, "Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B : a systematic review and meta-analysis", Hepatol Int, 14, pp.958~972 (2020)
- Fonseca MA, "The efficacy of hepatitis B treatments in achieving HBsAg seroclearance : a systematic review and meta-analysis", J Viral Hepat, 27, pp.650~662 (2020)
- Lim SG, "The scientific basis of combination therapy for chronic hepatitis B functional cure", Nat Rev Gastroenterol Hepatol, 20, pp.238~253 (2023)
- Jeng WJ, "What will it take to cure hepatitis B", Hepatol Commun, 7, pp.e0084~ (2023)
- Jeng WJ, "How to achieve a functional cure for chronic hepatitis B infection", Clin Liver Dis(Hoboken), 23, pp.e0134~ (2024)
- Lampertico P, "Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta : from clinical trials to real-world studies", J Hepatol, 77, pp.1422~1430 (2022)
- Gane E, "Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection", J Hepatol, 75(Suppl 2), pp.S736~ (2021)
- Yuen MF, "Long-term dosing with the capsid assembly modulator ALG-000184 results in multilog reductions of DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B subjects", Hepatology, 77, pp.5028~ (2023)
- Yuen MF, "Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression", J Hepatol, 75(Suppl 2), pp.S203~S204 (2021)
- Ganchua SC, "Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells", J Hepatol, 77(Suppl 1), pp.S851~ (2022)
- Hou J, "Efficacy and safety of Xalnesiran combination therapies with and without immunomodulator in virologically-suppressed participants with chronic hepatitis B : primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study(PIRANGA)", Hepatology, 77, pp.5006~ (2023)
- Bazinet M, "Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy", Gastroenterology, 158, pp.2180~2194 (2020)
- Gehring AJ, "Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection", J Hepatol, 77, pp.525~538 (2022)
- Sorensen H, "A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose Nivolumab in chronic hepatitis B infection", Hepatology, 77, pp.50~ (2023)
- Gao Z, "Phase 2 interim results : BRII-179(VBI-2601), a protein-based HBV therapeutic vaccine, induced robust HBsAb responses that are strongly associated with increased HBsAg loss in subjects receiving Peg-IFNαtreatment", Hepatology, 77, pp.5031~ (2023)
- Gane EJ, "VIR-2218 and VIR-3434with or without pegylated interferon alfa-2a for the treatment of chronic HBV infection : end of treatment(EOT)results after 24 weeks of therapy(MARCH study Part B)", Hepatology, 77, pp.5013~ (2023)
- Gane E, "Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B : a pilot study", J Hepatol, 71, pp.900~907 (2019)
- Wang G, "HBsAg loss in chronic hepatitis B patients after 24-week treatment with subcutaneously administered PD-L1 antibody ASC22(Envafolimab) : interim results from a phase IIb extension cohort", Hepatology, 77, pp.5052~ (2023)
- Kennedy PT, "Efficacy and safety of siRNA JNJ-73763989, capsid assembly modulator-E(CAME)JNJ-56136379, and nucleos(t)ide analogs(NA)with pegylated interferon alpha-2a(PEGIFN-α2a)added in immune-tolerant patients with chronic hepatitis B virus(HBV)infection : interim results from the phase 2 REEF-IT study", Hepatology, 77, pp.1468~ (2023)
- Buti M, "Pegylated interferon reduces relapses following Bepirovirsen treatment in participants with chronic hepatitis B infection on nucleos(t)ide analogues : end of study results from the phase 2b B-TOGETHER study", Hepatology, 77, pp.49~ (2023)